Given the increasing use of T-DXd across HER2-positive and HER2-low breast cancer as well as in other HER2 expressing malignancies, this case underscores the need for heightened clinical awareness and vigilance regarding potential hepatotoxic adverse events. This evidence concerns the gene ERBB2 and breast carcinoma.